Ge Z, Xu M, Ge Y, Huang G, Chen D, Ye X, Xiao Y, Zhu H, Yin R, Shen H, Ma G, Qi L, Wei G, Li D, Wei S, Zhu M, Ma H, Shi Z, Wang X, Ge X, Qian X (2023) Inhibiting G6PD by Quercetin promotes degradation of EGFR T790M mutation
Black M, Billing BH
JAMA Research Letter Links Semaglutide To Gastroparesis Risk A 2023 research letter in JAMA found that users of weight loss medications semaglutide and liraglutide, the active ingredient in Victoza and Saxenda, experienced gastroparesis nearly three times as often as those on bupropion-naltrexone (Contrave), another weight-loss drug
"They may advise you to restart on a lower dose or adjust your plan to reduce the risk of side effects," he explains
Prioritize activities